Affordable Access

deepdyve-link
Publisher Website

Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.

Authors
  • Wong, G K-C
  • Wong, R
  • Mok, V
  • Wong, A
  • Fan, D
  • Leung, G
  • Chan, A
  • Poon, W S
Type
Published Article
Journal
Journal of Clinical Pharmacy and Therapeutics
Publisher
Wiley (Blackwell Publishing)
Publication Date
Dec 01, 2009
Volume
34
Issue
6
Pages
657–663
Identifiers
DOI: 10.1111/j.1365-2710.2009.01056.x
PMID: 20175798
Source
Medline
License
Unknown

Abstract

The use of rivastigmine was safe in patients with spontaneous subarachnoid haemorrhage and persistent cognitive impairment. A prospective double-blind placebo-controlled trial is required to establish the efficacy of rivastigmine for patients with spontaneous subarachnoid hemorrhage and persistent cognitive impairment and whether it can be translated to improvement in instrumental activity of daily living and quality of life.

Report this publication

Statistics

Seen <100 times